Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 5/20 | 0.67 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.67 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.67 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.67 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.64 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.64 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | PLD1 | Q13393 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL319049 | 0.86 | CHRM1 (0.70) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL13081211 | 0.84 | OPRM1 (0.69) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL13351318 | 0.84 | CHRM1 (0.68) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL14593660 | 0.84 | CHRM1 (0.68) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL4152396 | 0.84 | CYP2D6 (0.70) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL14141301 | 0.83 | DRD2 (0.48) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL13801259 | 0.83 | SMN1; SMN2 (0.50) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL3142425 | 0.83 | CHRM1 (0.81) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL4084782 | 0.83 | CHRM1 (0.76) | CHRM1CHRM2CHRM4CHRM3OPRM1 | |
| SCHEMBL13801245 | 0.82 | CHRM1 (0.65) | CHRM1CHRM2CHRM4CHRM3OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011150457-A2 | HAEMATOPOIETIC-PROSTAGLANDIN D2 SYNTHASE INHIBITORS | THE UNIVERSITY OF QUEENSLAND (AU) | 2011-12-08 | — | — | WO | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | CHRM1 2/4885CHRM2 6/4885CHRM4 20/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.